Munich, Germany, December 20, 2011 -- SurgicEye®, the leading provider of intraoperative soft tissue imaging and navigation solutions, announces its participation at the 2012 Arab Health Congress in Dubai, UAE.

The SurgicEye team including Dr. Joerg Traub, CEO and co-founder of SugicEye GmbH, will be present at the Arab Health Congress in Dubai January 23-26, 2012 in the German Pavilion, booth no. ZL33. To schedule an appointment please contact us at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

Dr. Traub will be presenting the SurgicEye’s declipseSPECT - the world’s first FDA and CE certified product for intra-operative 3D imaging of radioactive labeled structures using existing gamma probe technology. The declipseSPECT offers a 3D imaging and navigation suite for radio guided-surgery. The solution combines 3D imaging and image viewing as tool to resect labeled structures like tumors, metastases, and sentinel lymph nodes. Even small and deeper-seated lesions can be instantly localized and precisely differentiated. With the declipseSPECT sentinel lymph node biopsy procedures for melanoma and in the breast are more sensitive, more reliable, and less invasive. declipseSPECT is currently used in hospitals across Europe and ensures the highest quality patient outcome in breast surgery and dermatology surgery.

About SurgicEye
SurgicEye offers solutions for intraoperative 3-D imaging and instrument navigation. The recent product declipseSPECT of SurgicEye implements the so-called freehand SPECT technology for detection, localization and guided biopsy of sentinel lymph nodes in breast cancer, melanoma and head & neck malignancies. Clinical investigations in other tumor surgery domains promise a wide application domain and huge potential for quality assurance during surgery. It enables surgical procedures to be more sensitive, more reliable and less invasive. For more information on SurgicEye, please visit www.surgiceye.com.

Contact:
SurgicEye
Claudia Ramirez-Wiesner
O: +49 89 54 99 89 001
E: This e-mail address is being protected from spambots. You need JavaScript enabled to view it